PIPELINE

DRUG CANDIDATE

TARGET

AREA

PLATFORM

DISCOVERY

PRECLINICAL

Phase I

Phase II

RS-0139	Integrin	Oncology	SagittaTM Bir	ClinicalTrials.gov Identifier: NCT04261413
RS-0337	HER2	Oncology	SagittaTM Dui
RS-0461	Integrin	Oncology	SagittaTM Dui
RS-0625	Integrin	Oncology	SagittaTM Bir
RS-0735	Undisclosed	Oncology	SagittaTM Bir

DRUG	TARGET	AREA	PLATFORM	PHASE

RS-0139	Integrin	Oncology	SagittaTM Bir	PhI Dose Escalation
RS-0337	HER2	Oncology	SagittaTM Dui	Preclinical
RS-0461	Integrin	Oncology	SagittaTM Dui	Preclinical
RS-0625	Integrin	Oncology	SagittaTM Bir	Preclinical
RS-0735	Undisclosed	Oncology	SagittaTM Bir	Preclinical